Page last updated: 2024-11-09

tropisetron

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tropisetron: An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tropisetron : An indolyl carboxylate ester obtained by formal condensation of the carboxy group of indole-3-carboxylic acid with the hydroxy group of tropine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID656665
CHEMBL ID56564
CHEMBL ID1289230
CHEBI ID32269
CHEBI ID94647
SCHEMBL ID18299
SCHEMBL ID18297
SCHEMBL ID18298
SCHEMBL ID3953452
SCHEMBL ID13287285
MeSH IDM0132280

Synonyms (71)

Synonym
chebi:32269 ,
gtpl260
ics-205930
PDSP1_000776
icf 205-930
ics 205930
1h-indole-3-carboxylic acid, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo-
tropisetronum [inn-latin]
ics-205-930
tropisteron
1alphah,5alphah-tropan-3alpha-yl indole-3-carboxylate
NCGC00015984-01
PDSP2_000764
tropisetron
D02130
tropisetron (inn)
NCGC00161414-01
(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1h-indole-3-carboxylate
HMS2090D16
TKT ,
chembl56564 ,
bdbm50108392
[(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1h-indole-3-carboxylate
CHEMBL1289230
dtxcid40819895
dtxsid2044137 ,
cas-89565-68-4
tox21_110272
AKOS015969677
NCGC00015984-04
tropisetronum
6i819nik1w ,
tropisetron [inn:ban]
unii-6i819nik1w
HY-B0072
CS-1146
S5538
AB00698553-07
SCHEMBL18299
SCHEMBL18297
SCHEMBL18298
SCHEMBL3953452
tox21_110272_1
NCGC00161414-03
tropisetron [inn]
1.alpha.h,5.alpha.h-tropan-3.alpha.-yl indole-3-carboxylate
tropisetron [mi]
tropisetron [mart.]
tropisetron [who-dd]
AB00698553-09
SCHEMBL13287285
(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 1h-indole-3-carboxylate
CHEBI:94647
NCGC00390718-01
rel-(1r,3r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 1h-indole-3-carboxylate
DB11699
1h-indole-3-carboxylic acid [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester
Q27166461
ics205-930
Q29428
BRD-K50866992-003-10-3
BRD-K50866992-003-09-5
HMS3886M10
CCG-267308
EN300-18551093
mfcd00864399
89565-86-6
EN300-27122033
(1r,3s,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 1h-indole-3-carboxylate
sdz-ics-930 free base
Z2681891229

Research Excerpts

Overview

Tropisetron is an antagonist of the 5HT3 receptor that exhibits anti-fibrosis effects. It is an adjuvant for dezocine used in intravenous patient-controlled analgesia (PCA)

ExcerptReferenceRelevance
"Tropisetron is a 5-HT3 receptor antagonist that exerts protective effect against DN. "( The effect of tropisetron on oxidative stress, SIRT1, FOXO3a, and claudin-1 in the renal tissue of STZ-induced diabetic rats.
Aziz, SG; Naderi, R; Samadi, M, 2021
)
2.42
"Tropisetron is an antagonist of the 5HT3 receptor that exhibits anti-fibrosis effects."( Renoprotective effects of tropisetron through regulation of the TGF-β1, p53 and matrix metalloproteinases in streptozotocin-induced diabetic rats.
Habibi, P; Naderi, R; Nikibakhsh, AA; Pourheydar, B; Samadi, M, 2021
)
1.64
"Tropisetron is an adjuvant for dezocine used in intravenous patient-controlled analgesia (PCA) and has been reported to provide superior pain control. "( Compatibility and stability of dezocine and tropisetron in 0.9% sodium chloride injection for patient-controlled analgesia administration.
Chen, F; Chen, P; Zhou, BH, 2018
)
2.18
"Tropisetron is a 5-HT3 receptor antagonist and α7-nicotinic receptor partial agonist."( Tropisetron Facilitates Footshock Suppression of Compulsive Cocaine Seeking.
Shen, HW; Shi, J; Yu, ZP; Zhang, LY; Zhang, XQ; Zhou, YQ, 2019
)
2.68
"Tropisetron is an adjuvant for butorphanol used in intravenous patient-controlled analgesia (PCA) and has been reported to provide superior pain control. "( Stability of butorphanol-tropisetron mixtures in 0.9% sodium chloride injection for patient-controlled analgesia use.
Chen, FC; Li, P; Shi, XY; Yang, JG; Zhou, BH, 2015
)
2.16
"Tropisetron is an effective antiemetic drug which also can potently inhibit calcineurin."( Inhibition of calcineurin/NFAT pathway plays an essential role in renoprotective effect of tropisetron in early stage of diabetic nephropathy.
Alimoradi, H; Asgari, M; Barzegar-Fallah, A; Dehpour, AR; Razmi, A; Shafiei, M, 2015
)
1.36
"Tropisetron is an orthosteric ligand at both 5-HT"( The binding orientations of structurally-related ligands can differ; A cautionary note.
Leuenberger, M; Lochner, M; Ruepp, MD; Thompson, AJ; Wei, H, 2017
)
1.18
"Tropisetron is an effective antiemetic drug for chemotherapy-induced emesis."( The cardioprotective effects of an antiemetic drug, tropisetron, on cardiomyopathy related to doxorubicin.
Abbasi, A; Alimoradi, H; Asadi, F; Barzegar-Fallah, A; Dehpour, AR; Delfan, B; Hassanzadeh, G; Mohammadi-Rick, S, 2012
)
1.35
"Tropisetron is a long-acting 5HT3 receptor antagonist and was shown to be effective in the prevention of postoperative nausea and vomiting (PONV) after tonsillectomy. "( Early vs late intraoperative administration of tropisetron for the prevention of nausea and vomiting in children undergoing tonsillectomy and/or adenoidectomy.
Dillier, CM; Gerber, AC; Gross, D; Reuss, S; Weiss, M, 2006
)
2.03
"Tropisetron (ICS 205-930) is a novel drug that blocks serotonin (5-HT3) receptors and, at higher concentrations, potassium channels. "( Antiarrhythmic and hemodynamic effects of tropisetron in anesthetized rabbits.
Hof, A; Hof, RP; Novosel, D; Zierhut, W, 1993
)
1.99
"Tropisetron is a potent and selective serotonin 3 (5-hydroxytryptamine3; 5-HT3) receptor antagonist with antiemetic properties, probably mediated via antagonism of receptors both at peripheral sites and in the central nervous system. "( Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic.
Lee, CR; McTavish, D; Plosker, GL, 1993
)
3.17
"Tropisetron is an effective and well-tolerated agent in the prevention of chemotherapy-induced vomiting."( Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting.
Anderson, H; de Bruijn, KM; Howell, A; Logan, K; Sage, T; Thatcher, N, 1994
)
2.45
"Tropisetron is a highly potent, selective antagonist of 5HT3 receptors."( The anti-emetic efficacy and tolerability of tropisetron in patients conditioned with high-dose chemotherapy (with and without total body irradiation) prior to bone marrow transplantation.
Cass, Y; Drakos, P; Kapelushnik, J; Nagler, A; Naparstek, E; Or, R, 1994
)
1.27
"Tropisetron is a novel, potent and highly selective 5-HT3 receptor antagonist, which is active in the treatment of nausea and vomiting induced by highly emetogenic chemotherapeutic drugs such as cisplatin. "( Pharmacology, toxicology and human pharmacokinetics of tropisetron.
Kutz, K, 1993
)
1.98
"Tropisetron is a 5-HT3 receptor antagonist which suppresses nausea and vomiting induced by cancer chemotherapeutic agents. "( Compassionate use of tropisetron in patients at high risk of severe emesis.
Bleiberg, H; De Wasch, G; Dirix, LY; Paridaens, R; Tjean, M; Van Belle, S, 1993
)
2.05
"Tropisetron appears to be a highly effective, well tolerated, and simple to use antiemetic agent for patients receiving chemotherapy."( A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
Krzakowski, M; Lasota, W; Madej, G; Pawinski, A; Rogowski, W; Skoneczna, I, 1994
)
1.3
"Tropisetron is a novel selective antagonist of the type-3 serotonin (5-HT3) receptor, with proven efficacy in the control of emesis related to cancer treatment. "( Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin.
Athanassiadis, A; Damigos, D; Fountzilas, G; Giannakakis, T; Nicolaides, C; Pavlidis, N; Skarlos, D, 1998
)
3.19
"Tropisetron is a new, long-acting serotonin antagonist that is an effective antiemetic in adults."( Tropisetron reduces vomiting after tonsillectomy in children.
Ang, C; Habre, W; Sims, C, 1998
)
2.46
"Tropisetron is a new 5HT3 receptor antagonist and is successfully used in paediatric patients receiving cancer therapy."( [Tropisetron for prevention of nausea and vomiting in children undergoing tonsillectomy and/or adenoidectomy].
Dillier, CM; Gerber, AC; Weiss, M, 2000
)
1.94
"Tropisetron is a serotonin (5-hydroxytryptamine; 5-HT) antagonist that is primarily used in the prevention of chemotherapy-induced nausea and vomiting. "( Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting.
McClellan, KJ; Simpson, K; Spencer, CM, 2000
)
3.19
"Tropisetron is an effective anti-emetic drug to prevent nausea and vomiting caused by anti-tumor agents, and its adverse reactions are mild."( [The clinical effect of Tropisetron in the prevention of nausea and vomiting induced by anti-cancer drugs].
Cui, C; Wang, J; Yang, L, 2001
)
2.06
"Tropisetron is a 5-hydroxytryptamine subtype 3 receptor antagonist that is primarily used in the prevention of chemotherapy-induced nausea and vomiting. "( The prophylactic effect of tropisetron on epidural morphine-related nausea and vomiting: a comparison of dexamethasone with saline.
Chen, JY; Chu, CC; Ho, ST; So, EC; Tzeng, JI; Wang, JJ, 2002
)
2.05
"Tropisetron seems to be a promising and well tolerated drug in conjunction with extended radiotherapy of abdominal fields."( Tropisetron, a new 5-HT3-receptor antagonist, in the prevention of radiation-induced nausea, vomiting and diarrhoea.
Berglind, AM; Sorbe, B, 1992
)
2.45
"Tropisetron seems to be a promising and well-tolerated drug in conjunction with extended radiotherapy."( Tropisetron, a new 5-HT3 receptor antagonist, in the prevention of radiation-induced emesis.
Berglind, AM; de Bruijn, K; Sorbe, B, 1992
)
2.45
"Tropisetron is a novel antiserotoninergic drug with potent and specific activity against cancer chemotherapy-induced emesis. "( Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy.
Bonadonna, G; Bregni, M; Di Nicola, M; Gianni, AM; Siena, S, 1991
)
3.17

Effects

Tropisetron also has a partial agonistic effect on alpha-7 nicotinic acetylcholine receptors (α7 nAChRs).

Tropisetron has been corroborate to conduct a protective role in HC, but its specific etiology remains unclear. It also has a partial agonistic effect on alpha-7 nicotinic acetylcholine receptors (α7 nAChRs)

ExcerptReferenceRelevance
"Tropisetron also has a partial agonistic effect on alpha-7 nicotinic acetylcholine receptors (α7 nAChRs)."( Tropisetron But Not Granisetron Ameliorates Spatial Memory Impairment Induced by Chronic Cerebral Hypoperfusion.
Amiri, S; Divanbeigi, A; Nasehi, M; Vaseghi, S; Zarrindast, MR, 2020
)
2.72
"Tropisetron not only has an analgesic but probably also an antiphlogistic effect which can be attributed to the inhibited release of substance P and other neuropeptides from the nociceptors and the blocked release of phlogistic substances from macrophages, monocytes etc."( Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron.
Müller, W; Stratz, T, 2004
)
1.26
"Tropisetron has been corroborate to conduct a protective role in HC, but its specific etiology remains unclear."( Tropisetron Ameliorated Cyclophosphamide-Induced Hemorrhagic Cystitis via Restraining TLR-4/NF-κB and JAK1/STAT3 Signaling Pathways.
Du, Y; Guo, L; Ma, C; Wang, M, 2023
)
3.07
"Tropisetron also has a partial agonistic effect on alpha-7 nicotinic acetylcholine receptors (α7 nAChRs)."( Tropisetron But Not Granisetron Ameliorates Spatial Memory Impairment Induced by Chronic Cerebral Hypoperfusion.
Amiri, S; Divanbeigi, A; Nasehi, M; Vaseghi, S; Zarrindast, MR, 2020
)
2.72
"Tropisetron not only has an analgesic but probably also an antiphlogistic effect which can be attributed to the inhibited release of substance P and other neuropeptides from the nociceptors and the blocked release of phlogistic substances from macrophages, monocytes etc."( Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron.
Müller, W; Stratz, T, 2004
)
1.26
"Tropisetron has several pharmacological activities other than anti-emesis such as the stimulation of the gastric emptying and the inhibition of the diarrhea, visceral pain and anxiety."( [Pharmacological review of tropisetron].
Yokoyama, T, 1999
)
1.32

Actions

Tropisetron may enhance colonic motility in the early postoperative period. However, the gastrocolonic response was impaired thereafter.

ExcerptReferenceRelevance
"Tropisetron notably promotes both IL-10 gene expression and secretion."( Tropisetron balances immune responses via TLR2, TLR4 and JAK2/STAT3 signalling pathway in LPS-stimulated PBMCs.
Hemmatpur, A; Hosseini, N; Karimollah, A; Manshadi, MD, 2021
)
2.79
"Tropisetron may enhance colonic motility in the early postoperative period; however, the gastrocolonic response was impaired thereafter. "( Postoperative colonic motility after tropisetron and a standardized meal in patients undergoing conventional colorectal surgery.
Glatzle, J; Kasparek, MS; Koenigsrainer, A; Kreis, ME; Mueller, MH; Vogt, A; Zittel, TT, 2007
)
2.06

Treatment

Tropisetron treatment significantly reduced liver fat content (-29%), liver inflammation (-56%), and liver cell necrosis (-59%) in ob/ob mice. Treatment did not significantly change serotonin levels in controls.

ExcerptReferenceRelevance
"Tropisetron treatment also restored the normal level of SIRT1/3/7 genes expression in the Hyp + Trop group (p < 0.05)."( Tropisetron restores normal expression of BAD, SIRT1, SIRT3, and SIRT7 in the rat pressure overload-induced cardiac hypertrophy model.
Fakhrgholami, M; Hemmatpur, A; Karimollah, A; Safari, F; Travat, T, 2023
)
3.07
"Tropisetrone-treated animals (either 5 or 10 mg/kg) showed significantly lower tumor sizes at the day 24th after tumor induction."( Tropisetron attenuates tumor growth and progression in an experimental model of mouse lung cancer.
Bagheri, A; Bazi, A; Ghafouri, Z; Hosseini, SM; Kalantar, H; Mehrabadi, AR; Rashidi, M; Shiran, MR, 2020
)
2.72
"Tropisetron treatment reduced intestinal motility and almost completely blocked weight gain associated with glucose feeding; however, total caloric intake was not affected."( Treatment with the 5-HT3 antagonist tropisetron modulates glucose-induced obesity in mice.
Bergheim, I; Bischoff, SC; Kanuri, G; Volynets, V; Weber, S, 2009
)
1.35
"Tropisetron treatment significantly reduced liver fat content (-29%), liver inflammation (-56%), and liver cell necrosis (-59%) in ob/ob mice."( Serotonin receptor type 3 antagonists improve obesity-associated fatty liver disease in mice.
Bischoff, SC; Haub, S; Hubert, A; Ladel, I; Ritze, Y; Saum, K; Spruss, A; Trautwein, C, 2011
)
1.09
"Tropisetron treatment also increased hepatic p38 MAPK and HO-1 expression compared with vehicle-treated trauma-hemorrhaged rats."( Protective effect of tropisetron on rodent hepatic injury after trauma-hemorrhagic shock through P38 MAPK-dependent hemeoxygenase-1 expression.
Hwang, TL; Liu, FC; Tsai, YF; Yu, HP, 2012
)
1.42
"Tropisetron treatment did not significantly change serotonin levels in controls."( Plasma serotonin and histamine levels in hemodialysis-related pruritus are not significantly influenced by 5-HT3 receptor blocker and antihistaminic therapy.
Domröse, U; Dunker, N; Gollnick, H; Neumann, KH; Weisshaar, E, 2003
)
1.04
"Tropisetron treatment was compared with alizapride treatment. "( Use of anti-emetics after intragastric balloon placement: experience with three different drug treatments.
Lasters, B; Van Hee, R; Van Wiemeersch, S; Weyler, J, 2003
)
1.76
"Tropisetron treatment continued for up to 6 days at the same daily dose, administered orally."( Pharmacokinetics of the 5HT3 receptor antagonist tropisetron in children.
Drechsler, S; Erttmann, R; Faerber, L; Gaedicke, G; Grass, P; Hartmann, W; Henze, G; Kutz, K,
)
1.11
"Treatment with tropisetron reversed TNF-α, apoptotic index, and endocannabinoid system components."( Involvement of endocannabinoid system, inflammation and apoptosis in diabetes induced liver injury: Role of 5-HT3 receptor antagonist.
Amini, M; Bagheri, M; Naderi, R; Pourheydar, B; Saboory, E, 2020
)
0.9
"Treatment with tropisetron and granisetron markedly suppressed the clinical symptoms of EAE (p<0.001) and reduced leukocyte infiltration as well as demyelination in the spinal cord (p<0.05)."( Tropisetron diminishes demyelination and disease severity in an animal model of multiple sclerosis.
Aminian, A; Dehpour, AR; Ghazi-Khansari, M; Hassanzadeh, G; Javadi, S; Kafami, L; Mehr, SE; Noorbakhsh, F; Rahimian, R, 2013
)
2.17
"Treatment with tropisetron, but not granisetron, prevented increases in oxidative stress and tumour necrosis factor-α, decreased urinary cytokine excretion and albuminuria, and improved renal morphological damage."( Tropisetron ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats.
Alimoradi, H; Asadi, F; Asgari, M; Barzegar-Fallah, A; Dehpour, AR; Shafiei, M, 2015
)
2.2
"Pre-treatment with tropisetron, ondansetron or MDL72222 did not significantly modify nefopam antinociception in both tests. "( Modulation of paracetamol and nefopam antinociception by serotonin 5-HT(3) receptor antagonists in mice.
Coppé, MC; Gillardin, JM; Girard, P; Niedergang, B; Pansart, Y, 2009
)
0.68
"treatment with tropisetron in a large, clearly defined patient population with secondary fibromyalgia."( [Pain modification by the 5-HT3 receptor antagonist tropisetron in secondary fibromyalgias].
Müller, W; Stratz, T, 2002
)
0.9
"Treatment with tropisetron leads in a subgroup of FM patients to pain reduction."( Influence of tropisetron on the serum substance P levels in fibromyalgia patients.
Fiebich, B; Haus, U; Müller, W; Stratz, T, 2004
)
1.03
"Treatment with tropisetron did not change the CT-induced net luminal gain of water (+ 108 +/- 41)."( Effect of 5-hydroxytryptamine antagonists on cholera toxin-induced secretion in the human jejunum.
Beubler, E; Eherer, AJ; Hinterleitner, TA; Holzer-Petsche, U; Krejs, GJ; Petritsch, W, 1994
)
0.63
"Pretreatment with tropisetron (TROP), an antagonist at serotonin3 (5-HT3) and 5-HT4 receptors, increases intake of IMB to approximately 85% of control."( Meal patterns reveal differential effects of vagotomy and tropisetron on responses to indispensable amino acid deficiency in rats.
Dixon, KD; Erecius, LF; Gietzen, DW; Jiang, JC, 1996
)
0.86
"Pretreatment with tropisetron, a selective 5-HT3 (5-hydroxytriptamine) receptor antagonist, did not affect the emetic response evoked by ouabain."( Involvement of a peripheral mechanism in the emesis induced by cardiac glycosides in Suncus murinus.
Kakimoto, S; Matsuki, N; Saito, H, 1997
)
0.62

Toxicity

ExcerptReferenceRelevance
" Although no adverse event was observed, increases in GOT and GPT, whose cause and relation to the investigational drug were unknown, were noted in 2 cases."( [The antiemetic effect, safety and usefulness of tropisetron capsule in the treatment of nausea and vomiting induced by lower multiple dose of cisplatin].
Akasaka, Y; Akaza, H; Fukuii, I; Kinouchi, T; Machida, T; Ozono, S, 1995
)
0.55
" All doses of tropisetron were well tolerated; no tropisetron recipient discontinued treatment because of intolerance and no adverse effect could be plausibly correlated to tropisetron administration."( Safety, tolerability, efficacy and plasma concentrations of tropisetron after administration at five dose levels to children receiving cancer chemotherapy.
de Bruijn, KM; Lemerle, J; Olive, G; Pons, G; Rey, E; Simonetta-Chateauneuf, C; Stettler, ER; Suarez, A, 1994
)
0.89

Pharmacokinetics

The pharmacokinetic and metabolic dispositions of tropisetron were studied in 12 healthy male volunteers receiving a single oral dose of 62 or 312 mumol (20 or 100 mg) of [14C]tropisetra. Tropisetro had similar pharmacokinetics characteristics in elderly patients and renal patients, compared with healthy subjects.

ExcerptReferenceRelevance
" The pharmacokinetic and metabolic dispositions of tropisetron were studied in 12 healthy male volunteers receiving a single oral dose of 62 or 312 mumol (20 or 100 mg) of [14C]tropisetron."( Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans.
Baldeck, JP; Fischer, V; Tse, FL,
)
0.62
" Tropisetron had similar pharmacokinetic characteristics in elderly patients and renal patients, compared with healthy subjects."( Pharmacology, toxicology and human pharmacokinetics of tropisetron.
Kutz, K, 1993
)
1.44
" The method has been applied to pharmacokinetic analysis of unbound tropisetron in rat intravenous administration."( Measurement and pharmacokinetic study of unbound tropisetron in rat blood by microdialysis with high-performance liquid chromatography.
Chen, CF; Huang, CT; Tsai, TH, 1999
)
0.79
"A pharmacokinetic study in children was performed to assess whether the pharmacokinetic profile of tropisetron in pediatric patients in similar to that in adults."( Pharmacokinetics of the 5HT3 receptor antagonist tropisetron in children.
Drechsler, S; Erttmann, R; Faerber, L; Gaedicke, G; Grass, P; Hartmann, W; Henze, G; Kutz, K,
)
0.6
" and the pharmacokinetic parameters were estimated."( Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers.
Bucher, M; Färber, L; Grobecker, H; Kees, F; Mair, G; Mörike, K, 2001
)
0.58
" All tested pharmacokinetic parameters (AUC(inf), AUC(inf)(NL70), Cmax, Cmax(NL70), T(1/2), and Tec) were significantly different among four different genotypic groups."( Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects.
Bae, KS; Cho, JY; Chung, JY; Hong, KS; Jang, IJ; Kim, MK; Lee, DH; Lee, SH; Lim, HS; Min, B; Oh, DS; Shin, SG, 2003
)
0.56
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

Tropisetron (Navoban, Novaban) alone or in combination with dexamethasone is effective for the acute phase of cisplatin (CIS)-induced emesis.

ExcerptReferenceRelevance
" This study was conducted to evaluate parameters of serotonin metabolism following platinum-based chemotherapy given in combination with the serotonin type-3 antagonist tropisetron as an antiemetic agent."( Serotonin metabolism following platinum-based chemotherapy combined with the serotonin type-3 antagonist tropisetron.
de Vries, EG; Groenewegen, A; Kema, IP; Schröder, CP; Sleijfer, DT; van der Graaf, WT, 1995
)
0.7
"This study compared the efficacy and tolerability of tropisetron (Navoban, Novaban) alone or in combination with dexamethasone for the treatment of emesis induced by moderately emetogenic non-cisplatin chemotherapy."( Tropisetron alone or in combination with dexamethasone for the prevention and treatment of emesis induced by non-cisplatin chemotherapy: a randomized trial.
Adams, M; Anderson, H; Barley, V; Boesen, E; de Bruijn, KM; Rüfenacht, E; Soukop, M; Trask, CW; Yosef, H, 1995
)
1.98
" Tropisetron in combination with dexamethasone produced the best control of both acute and delayed emesis."( Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Bruntsch, U; Drechsler, S; Eggert, J; Faerber, L; Gosse, H; Imhoff, W; Ukena, D, 1994
)
1.44
"Dexamethasone (20 mg) or its equivalent in combination with 5-HT3 antagonists appears to be the gold-standard dose for antiemetic prophylaxis."( Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting.
Blauth-Eckmeyer, E; Müller, H; Münstedt, K; Stenger, K; Vahrson, H; Zygmunt, M, 1999
)
0.3
"The anti-emetic efficacy of prophylactic ondansetron and tropisetron in combination with a low dose of droperidol in patients with high probability for post-operative nausea and vomiting undergoing gynaecological laparoscopy was compared."( Comparison of ondansetron and tropisetron combined with droperidol for the prevention of emesis in women with a history of post-operative nausea and vomiting.
Ala-Kokko, TI; Jokela, R; Koivuranta, M; Ranta, P, 1999
)
0.84
" reduces pain in tendinopathies to the same degree as a local injection of corticosteroids in combination with local anesthetic."( Local treatment of tendinopathies: a comparison between tropisetron and depot corticosteroids combined with local anesthetics.
Färber, L; Müller, W; Stratz, Th, 2002
)
0.56
" or 10 mg dexamethasone combined with 60 mg lidocaine was administered around the affected tendon."( Local treatment of tendinopathies: a comparison between tropisetron and depot corticosteroids combined with local anesthetics.
Färber, L; Müller, W; Stratz, Th, 2002
)
0.56
" tropisetron) combined with dexamethasone are effective for the acute phase of cisplatin (CIS)-induced emesis."( The antiemetic interaction of Delta9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew.
Darmani, NA; McClanahan, BA; Ray, AP; Wang, Y, 2009
)
1.49
"Sixty-two female patients undergoing elective LSG were randomly assigned to the TEAS combined with dexamethasone and tropisetron (TEAS group, n = 31) or dexamethasone and tropisetron (control group, n = 31) groups."( Transcutaneous Electrical Acupoint Stimulation Combined with Dexamethasone and Tropisetron Prevents Postoperative Nausea and Vomiting in Female Patients Undergoing Laparoscopic Sleeve Gastrectomy: a Prospective, Randomized Controlled Trial.
Liu, D; Ma, J; Min, S; Wei, K; Xiong, Q; Yang, Y; Zeng, M; Zou, L, 2021
)
1.06
"Objective To evaluate the effect of methylprednisolone sodium succinate combined with tropisetron on postoperative nausea and vomiting(PONV)under microvascular decompression of hemifacial spasm."( [Application of Methylprednisolone Sodium Succinate Combined with Tropisetron in Prevention of Nausea and Vomiting under Microvascular Decompression of Hemifacial Spasm].
Fan, CG; Fang, JX; Hao, QP; Jiao, F; Liu, B; Liu, R; Song, HD; Wang, DL; Zhou, JR, 2021
)
1.08
"We evaluated the efficacy of electroacupuncture combined with tropisetron in treating carboprost tromethamine-induced nausea and vomiting during cesarean section under lumbar anesthesia."( Efficacy of Electroacupuncture Combined with Tropisetron in Treating Carboprost Tromethamine-Induced Nausea and Vomiting during Cesarean Section under Lumbar Anesthesia.
Chang, Y; Qu, M; Wei, Q; Yang, Q; Yao, Z; Yu, L, 2021
)
1.12
"Our study suggested that electroacupuncture combined with tropisetron could effectively relieve carboprost tromethamine-induced nausea and vomiting during cesarean section under lumbar anesthesia."( Efficacy of Electroacupuncture Combined with Tropisetron in Treating Carboprost Tromethamine-Induced Nausea and Vomiting during Cesarean Section under Lumbar Anesthesia.
Chang, Y; Qu, M; Wei, Q; Yang, Q; Yao, Z; Yu, L, 2021
)
1.13
" Here, we retrospectively analyze CINV data of 100 patients who received either SEAM (semustine, etoposide, cytarabine, melphalan) or MEL140-200 (high-dose melphalan) before ASCT, evaluate the efficacy and safety of multiple-day administration of fosaprepitant combined with tropisetron and olanzapine (FTO), and compare the results to those of patients who received a standard regimen of aprepitant, tropisetron, and dexamethasone (ATD)."( Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study.
Cao, J; Chen, D; Du, X; Hu, Y; Jiang, L; Li, S; Liu, X; Lu, Y; Pei, R; Tang, S; Wang, T; Ye, P; Zhang, P, 2022
)
1.14
" The study was designed to assess the efficacy and safety of fosaprepitant combined with tropisetron and dexamethasone in preventing nausea and vomiting during 5 weeks of fractionated radiotherapy and concomitant weekly low-dose cisplatin chemotherapy in patients with CC or NPC."( Efficacy of fosaprepitant combined with tropisetron plus dexamethasone in preventing nausea and emesis during fractionated radiotherapy with weekly cisplatin chemotherapy: interim analysis of a randomized, prospective, clinical trial using competing risk
Cai, Q; Chen, C; Huang, K; Huang, R; Lin, X; Wang, R; Wang, S; Wu, Y; Xie, R; Xie, S; Yan, Y; Zeng, C; Zhan, Y, 2023
)
1.4

Bioavailability

Tropisetron exhibits a wide range of oral bioavailability at therapeutic doses, which is mainly determined by CYP2D6 activity. Whereas the absorption of oral doses of 62-312 mumol tropisetra was rapid and complete, bioavailability was estimated to be only 66% for the 312 mumol dose.

ExcerptReferenceRelevance
" Whereas the absorption of oral doses of 62-312 mumol tropisetron was rapid and complete, bioavailability was estimated to be only 66% for the 312 mumol dose and 52% for the 62 mumol dose, apparently because of saturable first-pass metabolism."( Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans.
Baldeck, JP; Fischer, V; Tse, FL,
)
0.61
"5 hours), and absolute bioavailability (41-42%) were identical in both age groups and comparable to those in adults."( Pharmacokinetics of the 5HT3 receptor antagonist tropisetron in children.
Drechsler, S; Erttmann, R; Faerber, L; Gaedicke, G; Grass, P; Hartmann, W; Henze, G; Kutz, K,
)
0.39
"To establish the bioavailability of tropisetron (5 mg) administered orally as capsule compared with 2 mg given intravenously."( Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers.
Bucher, M; Färber, L; Grobecker, H; Kees, F; Mair, G; Mörike, K, 2001
)
0.85
"Tropisetron exhibits a wide range of oral bioavailability at therapeutic doses, which is mainly determined by CYP2D6 activity."( Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers.
Bucher, M; Färber, L; Grobecker, H; Kees, F; Mair, G; Mörike, K, 2001
)
2.02
" Because intestinal motility and permeability are also regulated through the bioavailability of serotonin (5-HT), we assessed markers of hepatic injury in serotonin reuptake transporter knockout (SERT(-/-)) and wild-type mice chronically exposed to different monosaccharide solutions (30% glucose or fructose solution) or water for 8 wk."( Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice.
Bergheim, I; Bischoff, SC; Brune, T; Haub, S; Kanuri, G; Volynets, V, 2010
)
0.36
" Both vesicles demonstrated higher bioavailability relative to ethosomes, topical and oral aqueous solutions."( Tailoring novel soft nano-vesicles 'Flexosomes' for enhanced transdermal drug delivery: Optimization, characterization and comprehensive ex vivo - in vivo evaluation.
Abdel-Messih, HA; Geneidi, AS; Ishak, RAH; Mansour, S, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Previous studies evaluating the efficacy and tolerance of tropisetron for the treatment of fibromyalgia (FM) used the drug either intravenously or orally, and at different dosage levels ranging from 2 mg to 15 mg daily. The two cases give cause for clarifying this by means of clinical studies.

ExcerptRelevanceReference
" The 5-HT2 receptor antagonist ketanserin (1 microM) caused a clear rightward shift of the dose-response curve to 5-HT on the guinea-pig ganglion, but not on the mouse or rat ganglion."( Evidence that the 5-HT3 receptors of the rat, mouse and guinea-pig superior cervical ganglion may be different.
Cheshire, SH; Gilbert, MJ; Newberry, NR, 1991
)
0.28
" Studies must be of a prospective, parallel-group design in which the new treatment is compared with the existing best available treatment, after optimal dosage schedules for each have been established."( Methodology of antiemetic trials.
de Bruijn, KM; McVie, JG, 1992
)
0.28
" The simple dosage schedule of either 1 injection or 1 capsule per day makes tropisetron ideal for both inpatient and outpatient treatment."( Tropisetron. A review of the clinical experience.
de Bruijn, KM, 1992
)
1.96
" Both MDL 72222 and MDL 73147EF produced flat dose-response curves, with significant inhibition of defensive analgesia at minimum effective doses of less than or equal to 10 and 300 micrograms/kg, respectively."( Attenuation of defensive analgesia in male mice by 5-HT3 receptor antagonists, ICS 205-930, MDL 72222, MDL 73147EF and MDL 72699.
Rodgers, RJ; Shepherd, JK, 1992
)
0.28
" PCPA pretreatment shifted the cocaine dose-response curve to the right and blocked the ability of zacopride to reverse cocaine-induced activity."( 5-HT3 receptor antagonists block cocaine-induced locomotion via a PCPA-sensitive mechanism.
Hitzemann, R; Svingos, AL, 1992
)
0.28
" Results from a dose-response experiment indicate that increasing the dose of 5-HT can transform an inhibitory response into a biphasic or even an excitatory response."( Electrophysiological analyses of serotonergic actions on neurons in hypothalamic ventromedial nucleus in vitro: receptor subtypes involved and implications for regulation of feeding and lordosis behaviors.
Kow, LM; Pfaff, DW; Tsai, YF; Wang, L, 1992
)
0.28
" In contrast, 2-DG antinociception on the jump test was significantly potentiated across the 120-min time course and across the 2-DG dose-response curve (100-650 mg/kg) by methysergide, ritanserin, and ICS-205,930 pretreatment."( 2-Deoxy-D-glucose antinociception and serotonin receptor subtype antagonists: test-specific effects in rats.
Bodnar, RJ; Fisher, MC, 1992
)
0.28
" Such an inverse relation between dose and efficacy suggests a bell-shaped dose-response curve, implying that doses lower than 15 mg might well prove to be more effective."( Efficacy of ICS 205-930, a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, in the prevention of migraine attacks. A complex answer to a simple question. ICS 205-930 Migraine Study Group.
Ferrari, MD; Hirt, D; Lataste, X; Notter, M; Wilkinson, M, 1991
)
0.28
") had no effects on duodenal intraluminal pressure, but reduced the responses to distension with a bell-shaped dose-response relationship."( The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension.
Moss, HE; Sanger, GJ, 1990
)
0.28
" Pretreatment with a selective 5-HT3-receptor antagonist, ICS 205-930 (10 micrograms/kg), caused a shift to the right in both the 5-HT and 2-methyl-5-HT dose-response curves."( Effect of 5-hydroxytryptamine on gastric motility and efferent gastric vagus nerve activity in rats.
Ikeda, T; Saito, H; Saito, Y; Togashi, H; Yoshioka, M, 1990
)
0.28
") caused a displacement to the right of both the dose-response curves of 5-HT-induced blood pressure increase and heart rate reduction."( Inhibition of the 5-HT-induced cardiogenic hypertensive chemoreflex by the selective 5-HT3 receptor antagonist ICS 205-930.
Berthold, H; Engel, G; Scholtysik, G, 1989
)
0.28
" Since the chronic chlordiazepoxide pretreatment did not prevent the hypolocomotion or hypophagia induced by mCPP at high dosage (5 mg/kg) these latter effects are unlikely to be secondary to anxiety."( Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists.
Curzon, G; Kennett, GA; Shah, K; Whitton, P, 1989
)
0.28
" ICS 205-930 caused a parallel shift to the right of the dose-response curve for 5-HT."( Activation of 5-HT3 receptor subtypes causes rapid excitation of rabbit parasympathetic neurones.
Akasu, T; Hasuo, H; Tokimasa, T, 1987
)
0.27
" Parallel, rightward shifts in dose-response curves were seen with these concentrations of antagonist, but at higher concentrations (10(-9) and 10(-8) M) there was a further rightward shift with reduction in slope and maximum of the curves."( The depolarizing action of 5-hydroxytryptamine on rabbit vagal afferent and sympathetic neurones in vitro and its selective blockade by ICS 205-930.
Round, A; Wallis, DI, 1986
)
0.27
" The lower dosage was administered to four subjects and the higher dosage to eight on 5 consecutive days, preceded and followed by 2 days of placebo treatment."( Effects of 5HT3 receptor antagonism by tropisetron on the sleep EEG and on nocturnal hormone secretion.
Guldner, J; Hohlfeldt, E; Holsboer, F; Lauer, CJ; Pollmächer, T; Rothe, B; Steiger, A, 1994
)
0.56
" To compare the efficacy and tolerability of standard dosage of tropisetron and ondansetron in controlling emesis induced by chemotherapeutic regimen not containing cisplatin."( [Tropisetron versus ondansetron in the prevention and control of emesis in patients undergoing chemotherapy with FAC/FEC for metastatic or surgically treated breast carcinoma].
Campora, E; Rosso, R; Simoni, C,
)
1.28
" To improve the control of chemotherapy-induced emesis, further investigations on the additional tropisetron dosing at 8 h after cisplatin infusion or the combination use of tropisetron and other antiemetics by a continuous 4 h period of observation and comparison are mandatory."( Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis.
Chang, TC; Cheng, HH; Hsieh, F; Lai, CH; Li, CL; Michael, BJ; Soong, YK; Tseng, CJ, 1996
)
0.8
" These experimental conditions are also suitable for analysis of the considered compounds in pharmaceutical dosage forms or in biological fluids."( Retention behaviour of anti-emetic serotonin antagonists in reversed phase high performance liquid chromatography.
Barbato, F; La Rotonda, MI; Quaglia, F, 1995
)
0.29
"6% acetic acid) in conscious rats with a bell-shaped dose-response curve."( Response heterogeneity of 5-HT3 receptor antagonists in a rat visceral hypersensitivity model.
Dahl, SG; Junien, JL; Langlois, A; Pascaud, X; Rivière, PJ, 1996
)
0.29
" To come closer to the most adequate dose, we started a prospective, single-blind, randomized trial investigating additional dosage of 8 or 20 mg dexamethasone to tropisetron (Navoban), a 5-HT3 receptor antagonist, in cis-platinum-containing chemotherapy."( Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting.
Blauth-Eckmeyer, E; Müller, H; Münstedt, K; Stenger, K; Vahrson, H; Zygmunt, M, 1999
)
0.5
"6 mg/kg), significantly shifted the methamphetamine dose-response curve to the left."( Effects of various serotonin agonists, antagonists, and uptake inhibitors on the discriminative stimulus effects of methamphetamine in rats.
Goldberg, SR; Kutkat, SW; Laufert, MD; Munzar, P; Nováková, J, 1999
)
0.3
"The efficacy and tolerability of tropisetron were studied in an open trial comprising a total of 30 patients with advanced non-small cell lung cancer undergoing high-dose, cisplatin-based chemotherapy (cisplatin dosage 100 mg/m2)."( Efficacy and tolerability of tropisetron in the prevention of cisplatin-induced nausea and vomiting in advanced non-small cell lung cancer.
Thongprasert, S, 2000
)
0.88
" The recommended oral and IV dosage of tropisetron is 5 mg once daily; there is no increase in efficacy with doses >5 mg."( Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting.
McClellan, KJ; Simpson, K; Spencer, CM, 2000
)
2.02
" The effects of 15 mg tropisetron were similar to placebo, thus suggesting a bell-shaped dose-response curve."( Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group.
Alten, R; Brückle, W; Färber, L; Kötter, I; Lautenschläger, J; Müller, W; Neeck, G; Peter, HH; Pongratz, D; Späth, M; Stratz, T; Zöller, B, 2000
)
0.91
" In this study a bell-shaped dose-response curve was seen."( Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients.
Brückle, W; Färber, L; Kötter, I; Lautenschläger, J; Müller, W; Neeck, G; Peter, HH; Pongratz, D; Späth, M; Stratz, TH; Welzel, D; Zöller, B, 2001
)
0.54
"It is well known that the 5-HT3 receptor tropisetron shows a bell-shaped dose-response curve in the treatment of pain associated with fibromyalgia."( Do cytochrome enzymes influence the therapeutic effect of tropisetron in fibromyalgia?
Kees, F; Müller, W; Stratz, T, 2003
)
0.83
" 5-Hydroxytrypamine(3) (5-HT(3)) receptor antagonists, when used alone, are unsatisfactory in the attenuation of emesis; Furthermore, consensus about their optimal dose, optimal dosing frequency and the combined use with other anti-emetic drugs are still controversial."( [Tropisetron in attenuation of nausea and vomiting in patients undergoing high-dose chemo-radiotherapy supported by autologous peripheral blood stem cell transplantation].
Ai, B; He, XH; Liu, P; Shi, YK; Yang, JL; Zhang, CG; Zhou, AP; Zhou, SY, 2004
)
1.23
" The two cases give cause for clarifying this by means of clinical studies, which should also investigate the question of dosage (possibly 5 mg tropisetron twice daily)."( Treatment of systemic sclerosis with the 5-HT3 receptor antagonist tropisetron.
Müller, W; Stratz, T, 2004
)
0.76
"Previous studies evaluating the efficacy and tolerance of tropisetron for the treatment of fibromyalgia (FM) used the drug either intravenously or orally, and at different dosage levels ranging from 2 mg to 15 mg daily."( Treatment of fibromyalgia with tropisetron--dose and efficacy correlations.
Färber, L; Haus, U; Pongratz, D; Späth, M; Stratz, T, 2004
)
0.85
" Some differences were noted in dosing subanalyses."( A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis.
Arnold, D; Grothey, A; Hinke, A; Jordan, K; Schmoll, HJ; Voigt, W; Wolf, HH, 2007
)
0.34
"Three stability-indicating assay methods were developed for the determination of tropisetron in a pharmaceutical dosage form in the presence of its degradation products."( HPLC, TLC, and first-derivative spectrophotometry stability-indicating methods for the determination of tropisetron in the presence of its acid degradates.
Abdel-Fattah, LS; El-Haddad, DA; El-Sherif, ZA; Kilani, KM,
)
0.57
" The antiemetic dose-response curves of tropisetron against both emetogens were U-shaped probably because larger doses of this antagonist behave as a partial agonist."( Synergistic antiemetic interactions between serotonergic 5-HT3 and tachykininergic NK1-receptor antagonists in the least shrew (Cryptotis parva).
Alkam, T; Amos, B; Chebolu, S; Darmani, NA, 2011
)
0.64
" In this study, we evaluated the motivation for drug seeking in cocaine self-administering rats exposed to an escalated dosing regimen that endeavored to mimic the characteristic of escalating drug intake in human addicts."( Tropisetron Facilitates Footshock Suppression of Compulsive Cocaine Seeking.
Shen, HW; Shi, J; Yu, ZP; Zhang, LY; Zhang, XQ; Zhou, YQ, 2019
)
1.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indolyl carboxylic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (62)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency16.78550.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency39.81070.180013.557439.8107AID1468
AR proteinHomo sapiens (human)Potency27.10680.000221.22318,912.5098AID743035; AID743054; AID743063
estrogen nuclear receptor alphaHomo sapiens (human)Potency30.45410.000229.305416,493.5996AID743069; AID743075; AID743079; AID743091
cytochrome P450 2D6Homo sapiens (human)Potency12.30180.00108.379861.1304AID1645840
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency17.72440.057821.109761.2679AID1159526; AID1159528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency31.62280.00207.533739.8107AID891
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency27.39140.000323.4451159.6830AID743065; AID743067
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.50120.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency6.20500.00106.000935.4813AID943; AID944
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Cellular tumor antigen p53Homo sapiens (human)Potency13.84530.002319.595674.0614AID651631; AID720552
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 3EHomo sapiens (human)Ki0.01450.00100.88359.9000AID6336; AID6344
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)3.16230.00011.00768.7800AID79833
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki0.00280.00000.887110.0000AID416399
5-hydroxytryptamine receptor 3BHomo sapiens (human)Ki0.01450.00100.87119.9000AID6336; AID6344
Acetylcholine receptor subunit alphaHomo sapiens (human)Ki27.00000.00553.31338.2000AID145855
Acetylcholine receptor subunit gammaHomo sapiens (human)Ki27.00000.00553.31338.2000AID145855
Muscarinic acetylcholine receptor M2Homo sapiens (human)IC50 (µMol)3.16230.00001.23267.7930AID79833
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki0.00530.00010.532610.0000AID254286
Muscarinic acetylcholine receptor M5Homo sapiens (human)IC50 (µMol)3.45000.00010.99178.0000AID625155
Muscarinic acetylcholine receptor M5Homo sapiens (human)Ki2.47900.00000.72926.9183AID625155
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki55.00000.00000.12345.5000AID146640
Acetylcholine receptor subunit betaHomo sapiens (human)Ki27.00000.00553.31338.2000AID145855
Neuronal acetylcholine receptor subunit beta-2Homo sapiens (human)IC50 (µMol)170.00000.00110.539010.0000AID146308
Neuronal acetylcholine receptor subunit beta-2Homo sapiens (human)Ki55.00000.00000.11173.5400AID146640
DRattus norvegicus (Norway rat)Ki0.01140.00010.610010.0000AID6285; AID6336
D(3) dopamine receptorRattus norvegicus (Norway rat)Ki0.00060.00010.25675.8000AID6285
5-hydroxytryptamine receptor 3AMus musculus (house mouse)Ki0.00380.00130.23781.4300AID6008
D(1B) dopamine receptorRattus norvegicus (Norway rat)Ki0.00060.00020.24622.0000AID6285
D(4) dopamine receptorRattus norvegicus (Norway rat)Ki0.00060.00020.18872.0000AID6285
Neuronal acetylcholine receptor subunit beta-4Homo sapiens (human)IC50 (µMol)1.80000.00181.67796.5000AID146148
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)0.48800.00010.86458.7096AID625222
Sodium-dependent serotonin transporterHomo sapiens (human)Ki0.25900.00000.70488.1930AID625222
Neuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)IC50 (µMol)1.80000.00181.31326.5000AID146148
Neuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)Ki16.00000.00000.65225.4000AID145991
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)Ki0.00180.00020.484110.0000AID5874; AID5896; AID5898; AID6041; AID6284; AID6285; AID6292; AID6298; AID6308
Neuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)Ki0.00690.00221.742710.0000AID254311; AID690406
Neuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)IC50 (µMol)170.00000.00110.491110.0000AID146308
Neuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)Ki55.00000.00000.11573.5400AID146640
5-hydroxytryptamine receptor 3AHomo sapiens (human)Ki0.00820.00000.74119.9000AID416399; AID6336; AID6344; AID6364; AID6369; AID690405
Neuronal acetylcholine receptor subunit alpha-7Mus musculus (house mouse)Ki0.00690.00120.12230.4800AID146789
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.54948.4000AID61535
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.00190.00000.437510.0000AID6285; AID6364
Acetylcholine receptor subunit deltaHomo sapiens (human)Ki27.00000.00553.31338.2000AID145855
5-hydroxytryptamine receptor 4Homo sapiens (human)Ki0.19950.00000.443910.0000AID416400
5-hydroxytryptamine receptor 3DHomo sapiens (human)Ki0.01450.00100.88359.9000AID6336; AID6344
5-hydroxytryptamine receptor 3CHomo sapiens (human)Ki0.01450.00100.88359.9000AID6336; AID6344
5-hydroxytryptamine receptor 3BMus musculus (house mouse)Ki0.00380.00130.26351.4300AID6008
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)Ki0.00180.00020.502310.0000AID5874; AID5896; AID5898; AID6041; AID6284; AID6285; AID6292; AID6298; AID6308
TransporterRattus norvegicus (Norway rat)Ki27.00000.00010.866710.0000AID145855
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 3EHomo sapiens (human)Kd0.05300.00000.02840.1060AID6026; AID6027
5-hydroxytryptamine receptor 3BHomo sapiens (human)Kd0.05300.00000.01370.1060AID6026; AID6027
Neuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)EC50 (µMol)1.30000.12802.80188.9000AID220451; AID690407
5-hydroxytryptamine receptor 3AHomo sapiens (human)Kd0.05300.00000.00980.1060AID6026; AID6027
Neuronal acetylcholine receptor subunit alpha-7Rattus norvegicus (Norway rat)EC50 (µMol)0.65500.00021.848110.0000AID1238217; AID146796
5-hydroxytryptamine receptor 3DHomo sapiens (human)Kd0.05300.00000.02840.1060AID6026; AID6027
5-hydroxytryptamine receptor 3CHomo sapiens (human)Kd0.05300.00000.02840.1060AID6026; AID6027
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 3EHomo sapiens (human)Kb0.00930.00930.01390.0194AID5963
5-hydroxytryptamine receptor 3BHomo sapiens (human)Kb0.00930.00930.01390.0194AID5963
5-hydroxytryptamine receptor 3AHomo sapiens (human)Kb0.00930.00930.01390.0194AID5963
5-hydroxytryptamine receptor 4 Mus musculus (house mouse)Log Ki0.00620.00620.00620.0062AID6212
5-hydroxytryptamine receptor 3DHomo sapiens (human)Kb0.00930.00930.01390.0194AID5963
5-hydroxytryptamine receptor 3CHomo sapiens (human)Kb0.00930.00930.01390.0194AID5963
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (270)

Processvia Protein(s)Taxonomy
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3EHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3EHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3EHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3EHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3BHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3BHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3BHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
neuromuscular synaptic transmissionAcetylcholine receptor subunit alphaHomo sapiens (human)
neuromuscular junction developmentAcetylcholine receptor subunit alphaHomo sapiens (human)
regulation of membrane potentialAcetylcholine receptor subunit alphaHomo sapiens (human)
skeletal muscle contractionAcetylcholine receptor subunit alphaHomo sapiens (human)
monoatomic cation transportAcetylcholine receptor subunit alphaHomo sapiens (human)
neuronal action potentialAcetylcholine receptor subunit alphaHomo sapiens (human)
monoatomic ion transmembrane transportAcetylcholine receptor subunit alphaHomo sapiens (human)
regulation of membrane potentialAcetylcholine receptor subunit alphaHomo sapiens (human)
muscle cell cellular homeostasisAcetylcholine receptor subunit alphaHomo sapiens (human)
skeletal muscle tissue growthAcetylcholine receptor subunit alphaHomo sapiens (human)
musculoskeletal movementAcetylcholine receptor subunit alphaHomo sapiens (human)
neuromuscular processAcetylcholine receptor subunit alphaHomo sapiens (human)
excitatory postsynaptic potentialAcetylcholine receptor subunit alphaHomo sapiens (human)
neuron cellular homeostasisAcetylcholine receptor subunit alphaHomo sapiens (human)
membrane depolarizationAcetylcholine receptor subunit alphaHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholine receptor subunit alphaHomo sapiens (human)
response to nicotineAcetylcholine receptor subunit alphaHomo sapiens (human)
synaptic transmission, cholinergicAcetylcholine receptor subunit alphaHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
muscle contractionAcetylcholine receptor subunit gammaHomo sapiens (human)
signal transductionAcetylcholine receptor subunit gammaHomo sapiens (human)
synaptic transmission, cholinergicAcetylcholine receptor subunit gammaHomo sapiens (human)
monoatomic ion transmembrane transportAcetylcholine receptor subunit gammaHomo sapiens (human)
excitatory postsynaptic potentialAcetylcholine receptor subunit gammaHomo sapiens (human)
membrane depolarizationAcetylcholine receptor subunit gammaHomo sapiens (human)
chemical synaptic transmissionAcetylcholine receptor subunit gammaHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholine receptor subunit gammaHomo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membrane organizationAcetylcholine receptor subunit betaHomo sapiens (human)
monoatomic cation transportAcetylcholine receptor subunit betaHomo sapiens (human)
muscle contractionAcetylcholine receptor subunit betaHomo sapiens (human)
signal transductionAcetylcholine receptor subunit betaHomo sapiens (human)
synaptic transmission, cholinergicAcetylcholine receptor subunit betaHomo sapiens (human)
neuromuscular synaptic transmissionAcetylcholine receptor subunit betaHomo sapiens (human)
monoatomic ion transmembrane transportAcetylcholine receptor subunit betaHomo sapiens (human)
behavioral response to nicotineAcetylcholine receptor subunit betaHomo sapiens (human)
regulation of membrane potentialAcetylcholine receptor subunit betaHomo sapiens (human)
nervous system processAcetylcholine receptor subunit betaHomo sapiens (human)
muscle cell developmentAcetylcholine receptor subunit betaHomo sapiens (human)
excitatory postsynaptic potentialAcetylcholine receptor subunit betaHomo sapiens (human)
membrane depolarizationAcetylcholine receptor subunit betaHomo sapiens (human)
chemical synaptic transmissionAcetylcholine receptor subunit betaHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholine receptor subunit betaHomo sapiens (human)
response to hypoxiaNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
calcium ion transportNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
smooth muscle contractionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
visual perceptionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
sensory perception of soundNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
learningNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
memoryNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
locomotory behaviorNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
associative learningNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
visual learningNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of dopamine secretionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
sensory perception of painNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
vestibulocochlear nerve developmentNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
optic nerve morphogenesisNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
lateral geniculate nucleus developmentNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
central nervous system projection neuron axonogenesisNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
positive regulation of B cell proliferationNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of synaptic transmission, dopaminergicNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
positive regulation of dopamine secretionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
behavioral response to nicotineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
social behaviorNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of dopamine metabolic processNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
B cell activationNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to cocaineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of circadian sleep/wake cycle, REM sleepNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to ethanolNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
negative regulation of action potentialNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of dendrite morphogenesisNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
nervous system processNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
cognitionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of synapse assemblyNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
synaptic transmission involved in micturitionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to acetylcholineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
smooth muscle contractionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
regulation of smooth muscle contractionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
locomotory behaviorNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
neuronal action potentialNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
behavioral response to nicotineNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
regulation of neurotransmitter secretionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
positive regulation of transmission of nerve impulseNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
synaptic transmission involved in micturitionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
regulation of smooth muscle contractionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
nervous system developmentNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
locomotory behaviorNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
regulation of acetylcholine secretion, neurotransmissionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
behavioral response to nicotineNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
regulation of membrane potentialNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
regulation of dendrite morphogenesisNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
synaptic transmission involved in micturitionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
response to acetylcholineNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
negative regulation of tumor necrosis factor productionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to hypoxiaNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of protein phosphorylationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium ion transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
intracellular calcium ion homeostasisNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
learning or memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
short-term memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of cell population proliferationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
negative regulation of tumor necrosis factor productionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of MAPK cascadeNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of angiogenesisNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synapse organizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
cognitionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
sensory processingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of protein metabolic processNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
dendritic spine organizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
modulation of excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
dendrite arborizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of long-term synaptic potentiationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of amyloid-beta formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
negative regulation of amyloid-beta formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of amyloid precursor protein catabolic processNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to amyloid-betaNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to acetylcholineNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of amyloid fibril formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of CoA-transferase activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of membrane potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
action potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
response to hypoxiaNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
DNA repairNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
calcium ion transportNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
response to oxidative stressNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
regulation of dopamine secretionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
sensory perception of painNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
behavioral response to nicotineNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
B cell activationNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
regulation of membrane potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
nervous system processNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
cognitionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
inhibitory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3AHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
skeletal muscle contractionAcetylcholine receptor subunit deltaHomo sapiens (human)
monoatomic cation transportAcetylcholine receptor subunit deltaHomo sapiens (human)
muscle contractionAcetylcholine receptor subunit deltaHomo sapiens (human)
signal transductionAcetylcholine receptor subunit deltaHomo sapiens (human)
synaptic transmission, cholinergicAcetylcholine receptor subunit deltaHomo sapiens (human)
monoatomic ion transmembrane transportAcetylcholine receptor subunit deltaHomo sapiens (human)
skeletal muscle tissue growthAcetylcholine receptor subunit deltaHomo sapiens (human)
musculoskeletal movementAcetylcholine receptor subunit deltaHomo sapiens (human)
neuromuscular processAcetylcholine receptor subunit deltaHomo sapiens (human)
excitatory postsynaptic potentialAcetylcholine receptor subunit deltaHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholine receptor subunit deltaHomo sapiens (human)
chemical synaptic transmissionAcetylcholine receptor subunit deltaHomo sapiens (human)
membrane depolarizationAcetylcholine receptor subunit deltaHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 4Homo sapiens (human)
maintenance of gastrointestinal epithelium5-hydroxytryptamine receptor 4Homo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 4Homo sapiens (human)
mucus secretion5-hydroxytryptamine receptor 4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 4Homo sapiens (human)
large intestinal transit5-hydroxytryptamine receptor 4Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 4Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 4Homo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3DHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3DHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3DHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3CHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3CHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3CHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (71)

Processvia Protein(s)Taxonomy
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3EHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3EHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3BHomo sapiens (human)
acetylcholine receptor activityAcetylcholine receptor subunit alphaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit alphaHomo sapiens (human)
acetylcholine bindingAcetylcholine receptor subunit alphaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit alphaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialAcetylcholine receptor subunit alphaHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingAcetylcholine receptor subunit gammaHomo sapiens (human)
channel activityAcetylcholine receptor subunit gammaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialAcetylcholine receptor subunit gammaHomo sapiens (human)
acetylcholine receptor activityAcetylcholine receptor subunit gammaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit gammaHomo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
acetylcholine receptor activityAcetylcholine receptor subunit betaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit betaHomo sapiens (human)
protein bindingAcetylcholine receptor subunit betaHomo sapiens (human)
channel activityAcetylcholine receptor subunit betaHomo sapiens (human)
ligand-gated monoatomic ion channel activityAcetylcholine receptor subunit betaHomo sapiens (human)
acetylcholine bindingAcetylcholine receptor subunit betaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialAcetylcholine receptor subunit betaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit betaHomo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
ligand-gated monoatomic ion channel activityNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
protein-containing complex bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
quaternary ammonium group bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
heterocyclic compound bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
ligand-gated monoatomic ion channel activityNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
ligand-gated monoatomic ion channel activityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
amyloid-beta bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
toxic substance bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
chloride channel regulator activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
protein homodimerization activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
ligand-gated monoatomic ion channel activityNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit deltaHomo sapiens (human)
acetylcholine bindingAcetylcholine receptor subunit deltaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialAcetylcholine receptor subunit deltaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit deltaHomo sapiens (human)
acetylcholine receptor activityAcetylcholine receptor subunit deltaHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 4Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 4Homo sapiens (human)
serotonin receptor activity5-hydroxytryptamine receptor 4Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 4Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 3DHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3DHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3DHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 3CHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3CHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3CHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (55)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3EHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3EHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3EHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3EHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3BHomo sapiens (human)
cell surface5-hydroxytryptamine receptor 3BHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3BHomo sapiens (human)
neuromuscular junctionAcetylcholine receptor subunit alphaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit alphaHomo sapiens (human)
cell surfaceAcetylcholine receptor subunit alphaHomo sapiens (human)
neuromuscular junctionAcetylcholine receptor subunit alphaHomo sapiens (human)
postsynaptic membraneAcetylcholine receptor subunit alphaHomo sapiens (human)
postsynaptic specialization membraneAcetylcholine receptor subunit alphaHomo sapiens (human)
acetylcholine-gated channel complexAcetylcholine receptor subunit alphaHomo sapiens (human)
synapseAcetylcholine receptor subunit alphaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit alphaHomo sapiens (human)
neuron projectionAcetylcholine receptor subunit alphaHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneAcetylcholine receptor subunit gammaHomo sapiens (human)
postsynaptic membraneAcetylcholine receptor subunit gammaHomo sapiens (human)
acetylcholine-gated channel complexAcetylcholine receptor subunit gammaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit gammaHomo sapiens (human)
synapseAcetylcholine receptor subunit gammaHomo sapiens (human)
neuron projectionAcetylcholine receptor subunit gammaHomo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
neuromuscular junctionAcetylcholine receptor subunit betaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit betaHomo sapiens (human)
synapseAcetylcholine receptor subunit betaHomo sapiens (human)
postsynaptic specialization membraneAcetylcholine receptor subunit betaHomo sapiens (human)
acetylcholine-gated channel complexAcetylcholine receptor subunit betaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit betaHomo sapiens (human)
synapseAcetylcholine receptor subunit betaHomo sapiens (human)
neuron projectionAcetylcholine receptor subunit betaHomo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
external side of plasma membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
presynaptic membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
plasma membrane raftNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
cholinergic synapseNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
postsynaptic specialization membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
specific granule membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
tertiary granule membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
cholinergic synapseNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
endoplasmic reticulumNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
Golgi apparatusNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
postsynaptic densityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
nuclear speckNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
dendriteNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
neuronal cell bodyNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
plasma membrane raftNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membrane raftNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
postsynapseNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
external side of plasma membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
dendriteNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
neuronal cell bodyNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
cleavage furrow5-hydroxytryptamine receptor 3AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3AHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
neuromuscular junctionAcetylcholine receptor subunit deltaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit deltaHomo sapiens (human)
acetylcholine-gated channel complexAcetylcholine receptor subunit deltaHomo sapiens (human)
postsynaptic membraneAcetylcholine receptor subunit deltaHomo sapiens (human)
postsynaptic specialization membraneAcetylcholine receptor subunit deltaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit deltaHomo sapiens (human)
neuron projectionAcetylcholine receptor subunit deltaHomo sapiens (human)
synapseAcetylcholine receptor subunit deltaHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 4Homo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 4Homo sapiens (human)
endosome5-hydroxytryptamine receptor 4Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 4Homo sapiens (human)
membrane5-hydroxytryptamine receptor 4Homo sapiens (human)
synapse5-hydroxytryptamine receptor 4Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 4Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3DHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3CHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3CHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (163)

Assay IDTitleYearJournalArticle
AID375331Agonist activity at 5HT3 receptor in voltage-stimulated guinea pig left atrium assessed as positive inotropic potency at 100 uM2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Specific targeting of peripheral serotonin 5-HT(3) receptors. Synthesis, biological investigation, and structure-activity relationships.
AID183155Antagonist activity (100 mg/Kg) for the Bezold Jarisch reflex evoked by 30(mg/Kg) of 5-HT in ethylurethane anesthetized rats (i.v.)1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding.
AID180190The compound was evaluated for the inhibition of the von Bezold-Jarisch reflex in rat administered intravenously1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Indazoles as indole bioisosteres: synthesis and evaluation of the tropanyl ester and amide of indazole-3-carboxylate as antagonists at the serotonin 5HT3 receptor.
AID5992The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID254286Inhibition constant against 5-hydroxytryptamine 1A receptor2005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Designed multiple ligands. An emerging drug discovery paradigm.
AID183146Potency to inhibit bradycardiac effect measured by Von Bezold-Jarisch assay in 8 anesthetized rats1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.
AID5925Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID6105Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID146306Responses to that evoked by ACh at human Nicotinic acetylcholine receptor alpha4-beta2 expressed in xenopus oocytes up to 1 mM2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Activity of alpha7-selective agonists at nicotinic and serotonin 5HT3 receptors expressed in Xenopus oocytes.
AID5891Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
5-HT3 antagonists derived from aminopyridazine-type muscarinic M1 agonists.
AID6279Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Novel 5-HT3 antagonists: indol-3-ylspiro(azabicycloalkane-3,5'(4'H)-oxazoles).
AID1220557Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID416400Binding affinity at 5HT4 receptor2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.
AID61535Binding affinity towards Dopamine receptor D2 in rat was evaluated2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
Synthesis and pharmacology of isoquinuclidine derivatives as 5-HT(3) ligands.
AID6121Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Thiazole as a carbonyl bioisostere. A novel class of highly potent and selective 5-HT3 receptor antagonists.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID220450Functional activity is expressed as percent efficacy for alpha-7 nAChR.2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist.
AID146148Antagonism of ACh-evoked responses at human Nicotinic acetylcholine receptor alpha3-beta4 expressed in xenopus oocytes2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Activity of alpha7-selective agonists at nicotinic and serotonin 5HT3 receptors expressed in Xenopus oocytes.
AID6041In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Aromatic thiazole derivatives: structurally novel and selective serotonin-3 receptor antagonists.
AID177157In vivo effective dose against Bezold-Jarisch reflex evoked by 5-HT in urethane-anesthetized rats1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation.
AID146146Responses to that evoked by Nicotinic acetylcholine receptor alpha3-beta4 expressed in xenopus oocytes up to 1 mM2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Activity of alpha7-selective agonists at nicotinic and serotonin 5HT3 receptors expressed in Xenopus oocytes.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID5926Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID6364Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Thiazole as a carbonyl bioisostere. A novel class of highly potent and selective 5-HT3 receptor antagonists.
AID6255Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives.
AID60935-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID191058Percent response to 100 ug/kg serotonin was determined as blockade of serotonin-induced bradycardia in anesthetized rat1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Aromatic thiazole derivatives: structurally novel and selective serotonin-3 receptor antagonists.
AID1220559Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID5963Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID375337Agonist activity at 5HT3 receptor in guinea pig thoracic aorta assessed as positive contractility potency at 100 uM2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Specific targeting of peripheral serotonin 5-HT(3) receptors. Synthesis, biological investigation, and structure-activity relationships.
AID5927Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID6126Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg)1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
An initial three-component pharmacophore for specific serotonin-3 receptor ligands.
AID6011Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID5964Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.
AID6114Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID690405Inhibition of 5HT3 receptor2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Discovery and development of α7 nicotinic acetylcholine receptor modulators.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID6308Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis of a new class of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid derivatives as highly potent 5-HT3 receptor antagonists.
AID690406Binding affinity to alpha7 nAChR2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Discovery and development of α7 nicotinic acetylcholine receptor modulators.
AID5898Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.
AID60965-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1220560Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID60925-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats)1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID6177Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
Synthesis and pharmacology of isoquinuclidine derivatives as 5-HT(3) ligands.
AID375339Antagonist activity at 5HT3 receptor in spontaneously beating guinea pig right atrium assessed as inhibition of serotonin-induced maximum response by competitive binding assay2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Specific targeting of peripheral serotonin 5-HT(3) receptors. Synthesis, biological investigation, and structure-activity relationships.
AID179597Inhibition of the Bezold Jarisch reflex evoked by 30 ug/Kg of 5-HT.1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding.
AID254311Inhibition constant against nicotinic acetylcholine receptor alpha72005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Designed multiple ligands. An emerging drug discovery paradigm.
AID6292In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation.
AID79833Inhibition of 5-HT-evoked 5-HT4 receptor-mediated contractions in the guinea pig distal colon longitudinal muscle myenteric plexus (LMMP)1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
(1-Butyl-4-piperidinyl)methyl 8-amino-7-chloro-1,4-benzodioxane-5-carboxylate hydrochloride: a highly potent and selective 5-HT4 receptor antagonist derived from metoclopramide.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID145855In vitro Binding affinity towards alpha-1-beta-1-gamma-delta nAChR was determined2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID6310Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID6085Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Benzotriazinones as "virtual ring" mimics of o-methoxybenzamides: novel and potent 5-HT3 receptor antagonists.
AID146308Antagonism of ACh response at Nicotinic acetylcholine receptor alpha4-beta2 expressed in xenopus oocytes2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Activity of alpha7-selective agonists at nicotinic and serotonin 5HT3 receptors expressed in Xenopus oocytes.
AID1220558Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID146008Antagonism of ACh response at Nicotinic acetylcholine receptor alpha-3-beta-2-alpha-5 receptor expressed in xenopus oocytes up to 1 mM2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Activity of alpha7-selective agonists at nicotinic and serotonin 5HT3 receptors expressed in Xenopus oocytes.
AID6112Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID5968In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID145991In vitro Binding affinity towards alpha-3 (PC12) nAChR was determined2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist.
AID6256Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID5896In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding.
AID176402Effective dose that causes 50% reduction of serotonin effect in rats intravenously1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis of a new class of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid derivatives as highly potent 5-HT3 receptor antagonists.
AID1220555Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID6336Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID6026Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.
AID6369In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
An initial three-component pharmacophore for specific serotonin-3 receptor ligands.
AID6284Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.
AID6285Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.
AID375334Agonist activity at 5HT3 receptor in spontaneously beating guinea pig right atrium assessed as positive chronotropic potency at 100 uM2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Specific targeting of peripheral serotonin 5-HT(3) receptors. Synthesis, biological investigation, and structure-activity relationships.
AID220451Effective concentration that causes inhibition of alpha-7 nAChR, was determined. Values are expressed as EC50 +/- SEM.2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist.
AID146640In vitro Binding affinity towards Nicotinic acetylcholine receptor alpha4-beta2 was determined2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist.
AID6113Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID6054Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID180191The compound was evaluated for the inhibition of the von Bezold-Jarisch reflex in rat administered orally1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Indazoles as indole bioisosteres: synthesis and evaluation of the tropanyl ester and amide of indazole-3-carboxylate as antagonists at the serotonin 5HT3 receptor.
AID1220554Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID229404Selectivity ratio of peroral vs intravenous delivery1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Indazoles as indole bioisosteres: synthesis and evaluation of the tropanyl ester and amide of indazole-3-carboxylate as antagonists at the serotonin 5HT3 receptor.
AID6008The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Synthesis, in vitro binding profile, and central nervous system penetrability of the highly potent 5-HT3 receptor antagonist [3H]-4-(2-methoxyphenyl)-2-[4(5)-methyl-5(4)-imidazolylmethyl]thiazole.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID6027Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID185251Percent inhibition of serotonin-induced B-J reflex (Bezold-Jarisch reflex)in the right femoral vein of rat at a dose of 2 ug/kg1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Aromatic thiazole derivatives: structurally novel and selective serotonin-3 receptor antagonists.
AID5874Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
Synthesis and pharmacology of isoquinuclidine derivatives as 5-HT(3) ligands.
AID690407Agonist activity at alpha7 nAChR2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Discovery and development of α7 nicotinic acetylcholine receptor modulators.
AID690438Agonist activity at alpha7 nAChR relative to control2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Discovery and development of α7 nicotinic acetylcholine receptor modulators.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID6118Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID6212Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
5-HT4 receptor ligands: applications and new prospects.
AID185776Percentage inhibition 5-HT- mediated bradycardia in rat after 3 ug/Kg of compound administered intravenously1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.
AID1220556Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID146957Maximum responses to that evoked by ACh at human Nicotinic acetylcholine receptor alpha-7 expressed in xenopus oocytes2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Activity of alpha7-selective agonists at nicotinic and serotonin 5HT3 receptors expressed in Xenopus oocytes.
AID6087In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
5-Hydroxytryptamine (5-HT3) receptor antagonists. 3. Ortho-substituted phenylureas.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID411793Metabolic stability in human liver microsomes assessed as intrinsic clearance per mg of protein2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation.
AID146789In vitro Binding affinity towards alpha-7 nAChR was determined2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist.
AID6055Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID416399Binding affinity at 5HT3 receptor2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.
AID145998Responses to that evoked by Nicotinic acetylcholine receptor alpha3-beta2 expressed in xenopus oocytes up to 1 mM2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Activity of alpha7-selective agonists at nicotinic and serotonin 5HT3 receptors expressed in Xenopus oocytes.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1238217Partial agonist activity at rat alpha-7 nicotinic acetylcholine receptor expressed in Xenopus oocytes assessed as induction of currents2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Pharmacological profile of zacopride and new quaternarized fluorobenzamide analogues on mammalian α7 nicotinic acetylcholine receptor.
AID6344In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist.
AID146796Activation responses to that evoked by ACh at human Nicotinic acetylcholine receptor alpha-7 expressed in xenopus oocytes2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Activity of alpha7-selective agonists at nicotinic and serotonin 5HT3 receptors expressed in Xenopus oocytes.
AID6298pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.
AID5924Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID1346953Human 5-HT4 receptor (5-Hydroxytryptamine receptors)1997Journal of neurochemistry, Nov, Volume: 69, Issue:5
Cloning and expression of a human serotonin 5-HT4 receptor cDNA.
AID1346938Mouse 5-HT4 receptor (5-Hydroxytryptamine receptors)1996FEBS letters, Nov-25, Volume: 398, Issue:1
Cloning, expression and pharmacology of the mouse 5-HT(4L) receptor.
AID624238Antagonists at Human 5-Hydroxytryptamine receptor 5-HT42001Naunyn-Schmiedeberg's archives of pharmacology, Feb, Volume: 363, Issue:2
5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle.
AID624238Antagonists at Human 5-Hydroxytryptamine receptor 5-HT41997Journal of neurochemistry, Nov, Volume: 69, Issue:5
Cloning and expression of a human serotonin 5-HT4 receptor cDNA.
AID1346953Human 5-HT4 receptor (5-Hydroxytryptamine receptors)2001Naunyn-Schmiedeberg's archives of pharmacology, Feb, Volume: 363, Issue:2
5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle.
AID1346956Rat 5-HT4 receptor (5-Hydroxytryptamine receptors)1996European journal of pharmacology, May-23, Volume: 304, Issue:1-3
[3H]5-hydroxytryptamine labels the agonist high affinity state of the cloned rat 5-HT4 receptor.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (893)

TimeframeStudies, This Drug (%)All Drugs %
pre-199080 (8.96)18.7374
1990's434 (48.60)18.2507
2000's218 (24.41)29.6817
2010's117 (13.10)24.3611
2020's44 (4.93)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.56 (24.57)
Research Supply Index7.06 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index80.11 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials218 (23.09%)5.53%
Reviews54 (5.72%)6.00%
Case Studies14 (1.48%)4.05%
Observational1 (0.11%)0.25%
Other657 (69.60%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (20)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Glycopyrronium in Combination With Tropisetron in Anti-postoperative Nausea and Vomiting [NCT05331651]Phase 4480 participants (Actual)Interventional2022-04-08Completed
Observation on the Efficacy of Three Antiemetics in Preventing Nausea and Vomiting Caused by Intravenous Tramadol Injection and Postoperative Nausea and Vomiting [NCT05533281]Early Phase 1200 participants (Anticipated)Interventional2022-09-15Recruiting
A Multi-central Perspective Randomized Controlled Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation [NCT02576327]Phase 4130 participants (Anticipated)Interventional2015-10-31Active, not recruiting
Tropisetron With Risperidone for Schizophrenia [NCT00435370]Phase 3179 participants (Actual)Interventional2006-11-30Completed
Modulation of Central Hypersensitivity in Chronic Musculoskeletal Pain by Intravenous Tropisetron [NCT00889499]Phase 230 participants (Actual)Interventional2009-03-31Completed
The Central Analgesic Effects of Paracetamol on Serotonergic Pathways [NCT00970450]16 participants (Actual)Interventional2009-11-30Completed
Steroid-free Regimen With Aprepitant in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer Receiving FOLFOX Chemotherapy: a Randomized Phase 3 Trial [NCT02909478]Phase 3315 participants (Actual)Interventional2017-09-01Completed
[NCT00487110]Phase 440 participants (Anticipated)Interventional2008-06-30Completed
MyRisk: Efficacy and Safety Evaluation of Oral Akynzeo® in Patients Receiving MEC at High Risk of Developing CINV Based on a Prediction Tool: A Multinational and Multicenter Study [NCT04817189]Phase 4530 participants (Anticipated)Interventional2021-02-01Recruiting
The Efficacy and Safety of Tropisetron in Preventing Emergence Delirium: A Randomized Controlled Trial [NCT04027751]Phase 41,508 participants (Anticipated)Interventional2019-08-01Recruiting
A Single Arm Study to Evaluate the Control of Chemotherapy Induced Nausea and Vomiting in Non-Hodgkin Lymphoma Patients Receiving R-CHOP. [NCT01843868]130 participants (Anticipated)Interventional2013-05-31Not yet recruiting
Fosaprepitant Combined With Tropisetron Plus Dexamethasone in Preventing Nausea and Emesis During Fractionated Radiotherapy With Weekly Cisplatin Chemotherapy in Cervical Cancer and Nasopharyngeal Cancer [NCT05564286]Phase 3206 participants (Anticipated)Interventional2021-07-01Recruiting
Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE [NCT01895010]Phase 274 participants (Anticipated)Interventional2013-06-30Recruiting
A Korean Multicenter, Randomized, Double-Blind, Clinical Trial to Evaluate the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapies (MEC, Non-AC R [NCT01636947]Phase 4494 participants (Actual)Interventional2012-12-12Completed
A Randomized Phase II Trial of Acupressure and Acustimulation Wrist Bands for the Prevention of Chemotherapy-Induced Nausea and Vomiting [NCT00003817]Phase 2700 participants (Anticipated)Interventional1999-10-31Completed
Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer Receiving Anthracycline/Cyclophosphamide-containing Chemotherapy [NCT05242874]Phase 3403 participants (Anticipated)Interventional2022-01-01Recruiting
Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis [NCT02625181]27,034 participants (Actual)Interventional2016-07-31Completed
[NCT02478047]240 participants (Anticipated)Interventional2015-06-30Not yet recruiting
A Randomized, Double-blind, Placebo-controlled Pilot Trial Evaluating the Effect of Tropisetron on Prevention of Postoperative Cognitive Dysfunction in Patients After Cardiac Surgery [NCT04195204]Phase 472 participants (Anticipated)Interventional2020-11-01Recruiting
Transcutaneous Electrical Acupoint P6 Stimulation vs. Tropisetron Both in Combination With Dexamethasone to Prevent Postoperation Nausea and Vomiting in Women [NCT02096835]157 participants (Actual)Interventional2014-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00435370 (1) [back to overview]Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Cognition Domains
NCT01636947 (8) [back to overview]Number of Emetic Events - Overall Stage
NCT01636947 (8) [back to overview]Percentage of Participants With No Impact on Daily Life - Overall Stage
NCT01636947 (8) [back to overview]Percentage of Participants With No Vomiting and No Significant Nausea - Overall Stage
NCT01636947 (8) [back to overview]Percentage of Participants With One or More Clinical Adverse Event
NCT01636947 (8) [back to overview]The Percentage of Participants With No Vomiting - Overall Stage
NCT01636947 (8) [back to overview]Number of Participants With No Use of a Rescue Therapy - Overall, Acute, and Delayed Stages
NCT01636947 (8) [back to overview]Percentage of Participants With a Complete Response - Overall, Acute, and Delayed Stages
NCT01636947 (8) [back to overview]Percentage of Participants With No Vomiting - Acute and Delayed Stages
NCT02096835 (4) [back to overview]Need of Postoperative Metoclopramide
NCT02096835 (4) [back to overview]Number of Participants Experiencing Postoperative Nausea and Vomiting in 24h Postoperatively
NCT02096835 (4) [back to overview]Number of Participants Experiencing Postoperative Nausea in 24h Postoperatively
NCT02096835 (4) [back to overview]Number of Participants Experiencing Postoperative Vomiting in 24h Postoperatively
NCT02625181 (4) [back to overview]Adherence to PONV Guidelines
NCT02625181 (4) [back to overview]PONV Incidence: Number of Participants With Postoperative Nausea and Vomiting
NCT02625181 (4) [back to overview]The Number of Prophylactic Interventions for PONV
NCT02625181 (4) [back to overview]Time to Discharge From the Postanesthesia Care Unit (PACU)

Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Cognition Domains

"The following 8 scales are combined into a single index that is normalized with a mean score of 100 and a standard deviation of 10. Higher scores are considered better cognitive performance. No subscales scores are reported and a final standardized score is reported as the average of the standardized scores on each of these scales. Here is the listing of component scales that were translated into Chinese and used for this study:~Brief Assessment of Cognition in Schizophrenia (BACS): Symbol-Coding Trail Making Test: Part A Attention/Vigilance Continuous Performance Test-Identical Pairs (CPT-IP)* Wechsler Memory Scale®-3rd Ed. (WMS®-III): Spatial Span + Letter-Number Span Hopkins Verbal Learning Test-Revised™ (HVLT-R™) Brief Visuospatial Memory Test-Revised (BVMT-R™) Neuropsychological Assessment Battery® (NAB®): Mazes~Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT™):" (NCT00435370)
Timeframe: end of 12 wk treatment

Interventionunits on a scale (Mean)
Tropisetron96
Placebo95

[back to top]

Number of Emetic Events - Overall Stage

The number of emetic events that occurred during the Overall Stage (0 to 120 hours after initiation of MEC) are presented. (NCT01636947)
Timeframe: Hour 0 on Day 1 to Day 5 (approximately 120 hours)

InterventionNumber of Emetic Events (Number)
Aprepitant Regimen54
Control Regimen68

[back to top]

Percentage of Participants With No Impact on Daily Life - Overall Stage

"The Functional Living Index-Emesis questionnaire (FLIE) is a validated, participant-reported instrument to measure the impact of chemotherapy-induced nausea and vomiting on daily life. There are 9 nausea-related items and 9 vomiting-related items, each on a 7-point scale. For the purposes of this study, No Impact on daily life was defined as an average item score of >6 on the 7-point scale; a total score >108 indicates no impact on daily life. Overall Stage=0 to 120 hours after initiation of MEC." (NCT01636947)
Timeframe: Day 6

InterventionPercentage of Participants (Number)
Aprepitant Regimen76.8
Control Regimen73.8

[back to top]

Percentage of Participants With No Vomiting and No Significant Nausea - Overall Stage

"Nausea was to be assessed using a 100-mm horizontal visual analogue scale (VAS) located in the participant diary labeled: How much nausea have you had over the last 24 hours? The left end of the scale (0 mm) was labeled no nausea, and the right end of the scale (100 mm) is labeled nausea as bad as it could be. In this study, No Significant Nausea was defined as a VAS nausea rating <25 mm." (NCT01636947)
Timeframe: Days 1 to Day 5

InterventionPercentage of Participants (Number)
Aprepitant Regimen76.4
Control Regimen72.4

[back to top]

Percentage of Participants With One or More Clinical Adverse Event

An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition, which is temporally associated with the use of the study drug, is also an adverse event. Nausea and vomiting experienced during Days 1-6 were not counted as adverse events unless they were reported as a serious adverse event. (NCT01636947)
Timeframe: Day 1 through Day 29 (Up to 28 days after first dose of study drug)

InterventionPercentage of Participants (Number)
Aprepitant Regimen56.2
Control Regimen53.2

[back to top]

The Percentage of Participants With No Vomiting - Overall Stage

A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). No vomiting during the Overall Stage was defined as no episodes of emesis during the 120 hours (Days 1-5) after initiation of moderately emetogenic chemotherapy (MEC). (NCT01636947)
Timeframe: Hour 0 on Day 1 to Day 5 (approximately 120 hours)

InterventionPercentage of Participants (Number)
Aprepitant Regimen77.2
Control Regimen72.0

[back to top]

Number of Participants With No Use of a Rescue Therapy - Overall, Acute, and Delayed Stages

The percentage of participants who used no rescue therapy after initiation of MEC is presented for the Overall, Acute and Delayed Stages. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC. (NCT01636947)
Timeframe: Day 1 to Day 5

,
InterventionPercentage of Participants (Number)
Overall StageAcute StageDelayed Stage
Aprepitant Regimen84.898.784.8
Control Regimen87.799.288.5

[back to top]

Percentage of Participants With a Complete Response - Overall, Acute, and Delayed Stages

A Complete Response was defined as no vomiting or dry heaves and no use of a rescue therapy. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC. (NCT01636947)
Timeframe: Hour 0 on Day 1 to Day 5 (approximately 120 hours)

,
InterventionPercentage of Participants (Number)
Overall StageAcute StageDelayed Stage
Aprepitant Regimen73.495.874.3
Control Regimen70.497.971.2

[back to top]

Percentage of Participants With No Vomiting - Acute and Delayed Stages

A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC. (NCT01636947)
Timeframe: Day 1, Day 2 to Day 5

,
InterventionPercentage of Participants (Number)
Acute StageDelayed Stage
Aprepitant Regimen95.878.5
Control Regimen98.872.4

[back to top]

Need of Postoperative Metoclopramide

the number of patients who needed metoclopramide as a rescue medicine postoperatively (NCT02096835)
Timeframe: within 48h after operation

Interventionparticipants (Number)
Acustimulation5
Tropisetron4
Control7

[back to top]

Number of Participants Experiencing Postoperative Nausea and Vomiting in 24h Postoperatively

the total number including nausea, retching and vomiting within 24h after operation (NCT02096835)
Timeframe: within 24h after operation

Interventionparticipants (Number)
Acustimulation14
Tropisetron14
Control25

[back to top]

Number of Participants Experiencing Postoperative Nausea in 24h Postoperatively

(NCT02096835)
Timeframe: within 24h after the operation

Interventionparticipants (Number)
Acustimulation14
Tropisetron14
Control25

[back to top]

Number of Participants Experiencing Postoperative Vomiting in 24h Postoperatively

including retching and vomiting (NCT02096835)
Timeframe: within 24h after operation

Interventionparticipants (Number)
Acustimulation9
Tropisetron8
Control12

[back to top]

Adherence to PONV Guidelines

PONV guideline adherence: percentage of patients who received the exact number of prophylactic interventions for PONV that were recommended by the decision support. (NCT02625181)
Timeframe: A specific time frame on the day of surgery: the start of admission at the holding room to the end of the anesthetic case

InterventionParticipants (Count of Participants)
Baseline Measurement666
CDS Email Recommendations5260
CDS Email + Real TIme Recommenations5863

[back to top]

PONV Incidence: Number of Participants With Postoperative Nausea and Vomiting

The occurrence of PONV, as defined by the administration of antiemetics in the PACU between admission to PACU and discharge from PACU. (NCT02625181)
Timeframe: PACU recovery period

InterventionParticipants (Count of Participants)
Baseline Measurement139
CDS Email Recommendations1323
CDS Email + Real TIme Recommenations1343

[back to top]

The Number of Prophylactic Interventions for PONV

the absolute number of prophylactic interventions applied between the admission of the patient in the holding room until admission to the PACU. (NCT02625181)
Timeframe: A specific time frame on the day of surgery: from the start of admission at the holding room to the end of the anesthetic case

Interventionprophylactic antiemetics administered (Mean)
Baseline Measurement2.196
CDS Email Recommendations2.176
CDS Email + Real TIme Recommenations2.129

[back to top]

Time to Discharge From the Postanesthesia Care Unit (PACU)

This is the number of minutes from admission to the PACU until discharge, assessed up to 2 days (NCT02625181)
Timeframe: A specific time frame on the day of surgery: from the start of admission to the PACU to discharge from the PACU

Interventionminutes (Mean)
Baseline Measurement266
CDS Email Recommendations264
CDS Email + Real TIme Recommenations266

[back to top]